132 related articles for article (PubMed ID: 9845087)
1. Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection.
Zhang X; Melo T; Ballinger JR; Rauth AM
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):737-40. PubMed ID: 9845087
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
Ballinger JR; Kee JW; Rauth AM
J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.
Honess DJ; Hill SA; Collingridge DR; Edwards B; Brauers G; Powell NA; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):731-5. PubMed ID: 9845086
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of technetium-99m glucarate: in vitro cell cultures and in vivo tumour models.
Ballinger JR; Hsue V; Rauth AM
Nucl Med Commun; 2003 May; 24(5):597-606. PubMed ID: 12717079
[TBL] [Abstract][Full Text] [Related]
5. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
6. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
[TBL] [Abstract][Full Text] [Related]
7. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime.
Zhang X; Melo T; Rauth AM; Ballinger JR
Nucl Med Biol; 2001 Nov; 28(8):949-57. PubMed ID: 11711315
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic therapy and chemotherapy affect 99mTc sestamibi and 99mTc-HL91 accumulation differently in tumour xenografts.
Kinuya S; Yokoyama K; Fukuoka M; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Nucl Med Commun; 2005 Dec; 26(12):1067-73. PubMed ID: 16264352
[TBL] [Abstract][Full Text] [Related]
9. The biological characterization of (99m)Tc-BnAO-NI as a SPECT probe for imaging hypoxia in a sarcoma-bearing mouse model.
Hsia CC; Huang FL; Hung GU; Shen LH; Chen CL; Wang HE
Appl Radiat Isot; 2011 Apr; 69(4):649-55. PubMed ID: 21236690
[TBL] [Abstract][Full Text] [Related]
10. Labelling, control and radiopharmacological evaluation of 99mTc-adenosine 5'-diphosphate (99mTc-ADP) as tumour seeking agent.
León AS; Rey AM; Leon ET; Savio EO; Kremer C; Lacava CJ; Nappa AN; Chiozzone RN; Campos ED
Q J Nucl Med; 1996 Jun; 40(2):170-5. PubMed ID: 8909102
[TBL] [Abstract][Full Text] [Related]
11. [Biodistribution of hypoxic marker, 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)].
Suzuki T; Nakamura K; Kawase T; Kubo A
Kaku Igaku; 2001 Jul; 38(4):333-41. PubMed ID: 11530380
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91.
Kinuya S; Yokoyama K; Li XF; Bai J; Watanabe N; Shuke N; Takayama T; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1006-11. PubMed ID: 12173013
[TBL] [Abstract][Full Text] [Related]
13. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics.
Melo T; Hua HA; Ballinger JR; Rauth AM
Biochem Pharmacol; 1997 Sep; 54(6):685-93. PubMed ID: 9310345
[TBL] [Abstract][Full Text] [Related]
14. Tumour hypoxia and technetium tracers: in vivo studies.
Abrantes AM; Serra E; Goncalves C; Oliveiros B; Laranjo M; Sarmento-Ribeiro AB; Rocha-Gonsalves A; Botelho MF
Curr Radiopharm; 2012 Apr; 5(2):99-105. PubMed ID: 22280110
[TBL] [Abstract][Full Text] [Related]
15. BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein.
Cowan DS; Melo T; Park L; Ballinger JR; Rauth AM
Br J Cancer Suppl; 1996 Jul; 27():S264-6. PubMed ID: 8763894
[TBL] [Abstract][Full Text] [Related]
16. Preliminary studies of 99mTc-BnAO and its analogues: synthesis, radiolabeling and in vitro cell uptake.
Sun X; Chu T; Wang X
Nucl Med Biol; 2010 Feb; 37(2):117-23. PubMed ID: 20152710
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biological Evaluation of a New Nitroimidazole-99mTc-Complex for Imaging of Hypoxia in Mice Model.
Zhang Q; Zhang Q; Guan Y; Liu S; Chen Q; Li X
Med Sci Monit; 2016 Oct; 22():3778-3791. PubMed ID: 27752036
[TBL] [Abstract][Full Text] [Related]
18. Use of technetium-99m-liposomes in tumor imaging.
Goins B; Klipper R; Rudolph AS; Phillips WT
J Nucl Med; 1994 Sep; 35(9):1491-8. PubMed ID: 8071699
[TBL] [Abstract][Full Text] [Related]
19. A dual hypoxic marker technique for measuring oxygenation change within individual tumors.
Iyer RV; Kim E; Schneider RF; Chapman JD
Br J Cancer; 1998 Jul; 78(2):163-9. PubMed ID: 9683288
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime).
Suzuki T; Nakamura K; Kawase T; Kubo A
Ann Nucl Med; 2003 Apr; 17(2):131-8. PubMed ID: 12790362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
